Impact of Nebivolol on Central Aortic Pressure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2009-12-31

Study Completion Date

2010-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomized, cross-over, single-blind study to compare the effects of nebivolol and metoprolol on central aortic pressure and peripheral brachial pressure in patients with stable cardiovascular disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of the Long-term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension

NCT00142584

Hypertension

COMPLETED PHASE3

Efficacy and Safety of Nebivolol Versus Metoprolol in Hypertensive Subject Taking Amlodipine

NCT03635125

JNC 7 Stage 1 or 2 Hypertension

COMPLETED PHASE4

Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Plaques

NCT01230892

Atherosclerosis Endothelial Function

COMPLETED PHASE4

Nebivolol Versus Metoprolol: Sodium Sensitivity

NCT00992056

Hypertension

COMPLETED PHASE4

A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function

NCT01522950

Hypertension

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Central Aortic Pressure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nebivolol

Nebivolol therapy for 2-6 weeks depending on blood pressure readings

Group Type EXPERIMENTAL

Nebivolol

Intervention Type DRUG

10 mg by mouth daily for 2 weeks 20 mg by mouth daily for 2 weeks 40 mg by mouth daily for 2 weeks

Metoprolol

Metoprolol therapy for 2-6 weeks depending on blood pressure readings

Group Type EXPERIMENTAL

Metoprolol

Intervention Type DRUG

dosage prescribed prior to starting on study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nebivolol

10 mg by mouth daily for 2 weeks 20 mg by mouth daily for 2 weeks 40 mg by mouth daily for 2 weeks

Intervention Type DRUG

Metoprolol

dosage prescribed prior to starting on study

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects with history of hypertension
* Subjects who have received metoprolol for a minimum of 3 months

Exclusion Criteria

* Patients who have had an acute myocardial infarction, coronary revascularization or who have been hospitalized for heart failure or cardiac arrhythmia in the past 6 months

Minimum Eligible Age

45 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No